Adaptive Pharmacotherapy for Smoking Cessation

Completed · Phase 2 · Has a placebo group

Conditions studied: Nicotine Dependence

In brief

The purpose of this study is to assess an "adaptive" approach to smoking cessation pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the Nicotine Patch. The investigators hypothesize that participants allocated to adaptive therapy will show significantly higher biochemically confirmed 30-day continuous abstinence at 12 weeks post-Target Quit Day (TQD).

Key facts

Study ID

NCT02501265

Run by

Duke University

People needed

188

Starts

2017-06-06

Expected to finish

2021-05-12

Last updated by the study team

2021-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Actively smoking 5 or more cigarettes per day for at least one year
• Fluency in spoken and written English
• Willing to set a quit date within 6 weeks
• Access to a telephone
• Willingness to take Varenicline OR nicotine patch (patient choice)
• Willingness to take Bupropion

You may not qualify if…

• Daily use of a second form of tobacco or nicotine (e.g. e-cigarettes, cigars, chewing tobacco, snuff).
• Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, Bupropion).
• Report of pregnancy, attempting to get pregnant, or actively breast feeding or positive urine pregnancy test (only given to females with child bearing potential).
• Additional criteria may apply.

Where it is running

• Duke Center for Smoking Cessation — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.